Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. sold 15,400 shares of Abrdn Life Sciences Investors stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $11.67, for a total transaction of $179,718.00. Following the transaction, the insider now directly owns 3,078,916 shares in the company, valued at approximately $35,930,949.72. This trade represents a 0.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Saba Capital Management, L.P. also recently made the following trade(s):
- On Thursday, April 10th, Saba Capital Management, L.P. sold 30,156 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $11.14, for a total transaction of $335,937.84.
- On Friday, April 4th, Saba Capital Management, L.P. sold 6,889 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $11.57, for a total value of $79,705.73.
- On Wednesday, April 2nd, Saba Capital Management, L.P. sold 29,102 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $12.28, for a total value of $357,372.56.
- On Monday, March 31st, Saba Capital Management, L.P. sold 48,623 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $12.58, for a total value of $611,677.34.
- On Thursday, March 27th, Saba Capital Management, L.P. sold 32,922 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.01, for a total value of $428,315.22.
- On Wednesday, February 26th, Saba Capital Management, L.P. sold 200 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.62, for a total value of $2,724.00.
- On Wednesday, February 12th, Saba Capital Management, L.P. sold 36,536 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.75, for a total transaction of $502,370.00.
- On Monday, February 10th, Saba Capital Management, L.P. sold 42,987 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.95, for a total transaction of $599,668.65.
- On Monday, February 3rd, Saba Capital Management, L.P. sold 1,846 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.03, for a total transaction of $25,899.38.
- On Friday, January 31st, Saba Capital Management, L.P. sold 15,143 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.27, for a total value of $216,090.61.
Abrdn Life Sciences Investors Stock Performance
Shares of HQL opened at $11.81 on Wednesday. The business's fifty day moving average price is $12.95 and its 200 day moving average price is $13.78. Abrdn Life Sciences Investors has a 12-month low of $10.55 and a 12-month high of $15.90.
Abrdn Life Sciences Investors Cuts Dividend
The firm also recently declared a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Friday, February 21st were issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 15.93%. The ex-dividend date was Friday, February 21st.
Institutional Investors Weigh In On Abrdn Life Sciences Investors
Institutional investors have recently modified their holdings of the business. Sanctuary Advisors LLC lifted its holdings in Abrdn Life Sciences Investors by 11.4% in the third quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company's stock worth $183,000 after acquiring an additional 1,355 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Abrdn Life Sciences Investors by 7.3% in the 4th quarter. Janney Montgomery Scott LLC now owns 91,398 shares of the company's stock worth $1,199,000 after purchasing an additional 6,200 shares during the last quarter. Kingswood Wealth Advisors LLC acquired a new position in Abrdn Life Sciences Investors during the 4th quarter valued at approximately $160,000. Absolute Investment Advisers LLC bought a new position in Abrdn Life Sciences Investors during the 4th quarter worth $5,242,000. Finally, Wolverine Asset Management LLC acquired a new stake in Abrdn Life Sciences Investors in the fourth quarter worth $1,594,000. Institutional investors own 32.21% of the company's stock.
About Abrdn Life Sciences Investors
(
Get Free Report)
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
